


**In the Claims:**


**Claims 1 to 13 (cancelled).**

**Claim 14 (currently amended)**      A compound of ~~general~~ the formula (I')



wherein

A is



R<sub>18</sub>, R<sub>19</sub> and R<sub>20</sub> are independently selected from the group consisting of hydrogen, halogen, -OH, SR<sub>23</sub>, alkyl or alkoxy of 1 to 6 carbon atoms, ~~alkenyl of up to 6 carbon atoms and~~ NR<sub>24</sub>R<sub>25</sub>, R<sub>21</sub> and R<sub>22</sub> are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or R<sub>21</sub> and R<sub>22</sub> form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently selected from the group consisting of O, N or furthermore R<sub>21</sub> is selected

from the group consisting of alkylsulfonyl, alkylsulfoxide and alkylcarbonyl and then  $R_{22}$  is hydrogen,  $R_{23}$  is hydrogen or alkyl of 1 to 6 carbon atoms,  $R_{24}$  and  $R_{25}$  are independently selected from the group consisting of hydrogen, OH, alkyl of 1 to 6 carbon atoms and  $\text{CO}-R_{26}$ ,  $R_{26}$  is alkyl of 1 to 6 carbon atoms,

B is selected from the group consisting of alkyl of 1 to 6 carbon atoms,  $\text{NR}_{34}\text{R}_{35}$ , carbocyclic or heterocyclic aryl with 5 or 6 members containing from 1 to 4 heteroatoms selected from the group consisting of O, S and N, the aryl radical being optionally substituted by at least one member selected from the group consisting of alkyl or alkoxy of 1 to 6 carbon atoms and alkenyl of up to 6 carbon atoms thiophenyl,

$R_{34}$  and  $R_{35}$  are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or  $R_{34}$  and  $R_{35}$  form together with the nitrogen atom a non-aromatic heterocycle with five to six members, each of the elements of the chain being selected from the group consisting of  $\text{CH}_2$ , NH, O and S,

X is selected from the group consisting of a bond,  $-(\text{CH}_2)_m-$ ,  $-(\text{CH}_2)_m\text{CO}-$ ,  $\text{O}-(\text{CH}_2)_m-$ ,  $-\text{S}-(\text{CH}_2)_m-$ ,  $\text{NR}_{36}-(\text{CH}_2)_m-$ , or  $-\text{CO}-\text{NR}_{36}-$ ,  $-\text{O}-(\text{CH}_2)_m\text{CO}-$ ,  $-\text{S}-(\text{CH}_2)_m\text{CO}-$ ,  $\text{NR}_{36}-(\text{CH}_2)_m\text{CO}-$ ,  $-(\text{CH}_2)_m\text{C}(\text{OH})(\text{CH}_3)\text{CO}-$ ,  $\text{CH}=\text{CH}$  and  $\text{CH}=\text{N}-$ ,

Y is selected from the group consisting of a bond,  $-(\text{CH}_2)_n-$ , and  $-(\text{CH}_2)_r\text{Q}-(\text{CH}_2)_s-$ , and thiazolidine,

~~Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine, thiazolidine and a saturated carbon ring having 3 to 7 members,~~

~~$\Phi$  is selected from the group consisting of a bond,  $(\text{CH}_2)_p\text{-O-(CH}_2)_q$ ,  $(\text{CH}_2)_p\text{-S-(CH}_2)_q$ ,  $(\text{CH}_2)_p\text{-NR}_{37}\text{-(CH}_2)_q$ ,  $(\text{CH}_2)_p\text{-CO-NR}_{37}\text{-(CH}_2)_q$ , and  $\text{CO(CH}_2)_p\text{-NR}_{37}\text{-(CH}_2)_q$ ,~~

~~R<sub>36</sub> and R<sub>37</sub> are independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and -CO-R<sub>38</sub>, R<sub>38</sub> is alkyl or alkoxy of 1 to 6 carbon atoms,~~

~~R<sub>39</sub> is selected from the group consisting of hydrogen and alkyl or alkoxy of 1 to 6 carbon atoms,~~

~~m, n, p, q, r and s are independently integers from 0 to 6,~~

~~and its pharmaceutically acceptable salts.~~

**Cancel Claims 15 to 19.**

**Claim 20** (previously presented)      A compound of claim 14 selected from the group consisting of

---

- 2-amino-N-(4- {[amino(2-thienyl)methylidene]amino}phenethyl)-5-methoxybenzamide;

- 5-amino-N-(4-{{[amino(2-thienyl)methylidene]amino}phenethyl})-2-hydroxybenzamide;
- 4-(4-{{[amino(2-thienyl)methylidene]amino}phenyl})-N-{4-[(methylsulphonyl)amino]phenyl}butanamide;
- 4-(4-{{[amino(2-thienyl)methylidene]amino}phenyl})-N-[4-(dimethylamino)phenyl]butanamide;
- 5-(4-{{[amino(2-thienyl)methylidene]amino}phenyl})-N-[4-(dimethylamino)phenyl]pentanamide;
- (4*R*)-2-(3-{{[amino(2-thienyl)methylidene]amino}-phenyl})-N-[4-(dimethylamino)phenyl]-1,3-thiazolidine-4-carboxamide;
- *tert*-butyl 3-{{[amino(2-thienyl)methylidene]amino}benzyl}{3-[4-(dimethylamino)anilino]-3-oxopropyl}carbamate;
- 3-{{(3-{{[amino(2-thienyl)methylidene]amino}-benzyl)amino}-N-[4-(4-methyl-1-piperazinyl)phenyl])propanamide};
- 3-{{(3-{{[amino(2-thienyl)methylidene]amino}-benzyl)amino}-N-[4-(4-morpholinyl)phenyl])propanamide};
- N'-[4-(2-{{[5-(dimethylamino)-2-hydroxybenzyl]amino}ethyl})phenyl]-2-thiophenecarboximidamide;
- N-(4-{{{4-{{[amino(2-thienyl)methylidene]amino}phenethyl)-amino}methyl}phenyl)acetamide;
- N'-[4-(2-{{[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]amino}ethyl})phenyl]-2-thiophenecarboximidamide;
- N'-[4-[2-({[4-(dimethylamino)anilino]carbonyl)amino}ethyl]phenyl]-2-thiophenecarboximidamide;
- N'-[4-[2-{{[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-(methyl)amino}ethyl}phenyl]-2-thiophenecarboximidamide;

and the pharmaceutically acceptable salts of the latter.

**Claim 21 (withdrawn)**      A method of inhibiting NO synthase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

**Claim 22 (withdrawn)**      A method of inhibiting lipidic peroxidation in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

Cancel **Claim 23**.

**Claim 24 (withdrawn)**      A method of treating a neurodegenerative disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

**Claim 25 (withdrawn)**      The method of claim 24 wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeldt Jacob disease and amyotrophic lateral sclerosis.